Ibio Inc., of New York, which develops plant-based biopharmaceuticals, priced a public offering for expected gross proceeds of about $16 million. The offering consisted of 4.35 million shares of common stock priced at 90 cents apiece, 6,300 shares of series A convertible preferred stock and 5,785 shares of series B convertible preferred stock.